ABSTRACT
BACKGROUND: Clinically relevant postoperative pancreatic fistula (CR-POPF) is the most feared complication following pancreaticoduodenectomy (PD). There is increasing evidence that very early postoperative factors can be helpful to identify high-risk patients. The aim of this study is to analyze whether postoperative day one (POD1) systemic inflammatory response can be used as an early biomarker of CR-POPF development. METHODS: All patients undergoing PD from 2014 to 2020 were considered. Variables were extracted from a prospectively held database. Clinical and perioperative variables, including POD1 systemic inflammatory response syndrome (SIRS) and C-reactive protein level were collected. To elucidate the independent role of early CR-POPF biomarkers, multivariate hierarchical logistic regression analyses were planned. RESULTS: Out of 243, 213 patients were included in this analysis. CR-POPF occurred in 49 (23.0%) patients and 90-day mortality was 1.4%. POD1 SIRS was reported in 65 (30.5%) patients. Following hierarchical logistic regression analyses, CR-POPF was independently associated with body mass index (OR = 2.787, p = 0.003), soft pancreatic texture (OR = 4.258, p = 0.002) and POD1 SIRS (OR = 50.067, p = 0.001). CONCLUSION: POD1 SIRS is powerfully associated with CR-POPF and therefore it could be used as a tool to optimize postoperative care of PD patients. Further prospective studies are needed to validate these findings.
Subject(s)
Pancreas , Pancreatic Fistula , Humans , Pancreatic Fistula/diagnosis , Pancreatic Fistula/etiology , Risk Factors , Pancreas/surgery , Pancreaticoduodenectomy/adverse effects , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Postoperative Complications/surgery , Biomarkers , Retrospective StudiesABSTRACT
BACKGROUND: The Coronavirus pandemic outbreak in 2019 and the saturation of healthcare system led to an increased use of digital tools for surveillance. In this study we described our experience using telemedicine to follow-up on patients with intraductal papillary mucinous neoplasms during the COVID-19 era and analyze those factors associated to patients' satisfaction. METHODS: This 1-year retrospective observational study enrolled patients with intraductal papillary mucinous neoplasms followed-up by telemedicine during COVID-19 outbreak. Patients with high-risk features needing on-site physical examination or declining remote follow-up were excluded. A 13-question survey was conducted; demographic, geographic, and employment information was collected. Univariate and multivariate analyses were performed to evaluate those factors associated to patients' satisfaction. RESULTS: Out of 287, a total of 177 patients with intraductal papillary mucinous neoplasms were included: the mean age was 69 (44-87) years and the male/female ratio was 0.78. A total of 80 (45.2%) patients had previously experienced abdominal pain. Most patients (85.3%) were satisfied with telemedicine: at univariate analysis, age ≥70 years (P = .007), retirement (P = .001), and absence of previous abdominal pain (P = .05) were significantly associated with patient satisfaction. At multivariate analysis, the absence of previous abdominal pain was the only factor independently associated with patient satisfaction (odds ratio 5.964, 95% confidence interval 2.21-16.11, P < .001). CONCLUSION: Telemedicine allows a new follow-up strategy that can be used in selected patients with intraductal papillary mucinous neoplasms. The absence of previous abdominal pain is associated with patient satisfaction during follow-up. Further studies are needed to evaluate safety of remote follow-up in patients with intraductal papillary mucinous neoplasms.
Subject(s)
Adenocarcinoma, Mucinous , COVID-19 , Carcinoma, Pancreatic Ductal , Carcinoma, Papillary , Pancreatic Neoplasms , Telemedicine , Humans , Female , Male , Aged , Follow-Up Studies , Pancreatic Neoplasms/epidemiology , Pancreatic Neoplasms/therapy , Pancreatic Neoplasms/diagnosis , Disease Outbreaks , Abdominal PainABSTRACT
El tratamiento del infarto agudo del miocardio con activadores del plasminógeno representa un avance significativo de la farmacoterapia cardiovascular. Se describe 1a primera experiencia local del tratamiento de infarto del miocaradio con agentes trombolíticos administrados por vía intravenosa. Se estudian las indicaciones y los aspectos generales de la terapia trombolítica, la cual se ha convertido en el tratamiento de elección en ciertos pacientes con infarto agudo del miocardio
